Stewart L. Fisher

C4 Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index5.4kcitations90works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(22), Ubiquitin and proteasome pathways(13), Multiple Myeloma Research and Treatments(8), Bacterial Genetics and Biotechnology(7), Computational Drug Discovery Methods(7)

Publications90 total

Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
Journal of Medicinal Chemistry·2025· 3 cited
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
Cancer Research·2025· 1 cited
CFT8634, a potent, selective and orally bioavailable BiDACTM degrader of BRD9, highlights the potential of C4T’S TORPEDO® platform to develop degraders with excellent drug-like properties against currently undruggable targets
Drug Metabolism and Pharmacokinetics·2025
Determination of steady state brain KP,UU of BIDAC(TM) degraders using chemical knock out animal models
Drug Metabolism and Pharmacokinetics·2025
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex
Communications Chemistry·2024· 7 citedOpen Access
Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
Cancer Research·2024
Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Cancer Research·2024· 1 cited
Abstract P39: CFT7455, a novel IKZF1/3 degrader enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses
Blood Cancer Discovery·2024· 5 cited
CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide
Blood·2023· 15 cited
CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents
Hematological Oncology·2023· 5 citedOpen Access
Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Cancer Research·2023· 1 cited
Dataset from: Rapid radiation of ant parasitic butterflies during the Miocene aridification of Africa
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
Dataset from: Rapid radiation of ant parasitic butterflies during the Miocene aridification of Africa
DIGITAL.CSIC (Spanish National Research Council (CSIC))·2023Open Access
Rapid radiation of ant parasitic butterflies during the Miocene aridification of Africa
Ecology and Evolution·2023· 12 citedOpen Access
Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Cancer Research·2023· 10 cited
Phylogeny of the Poritiinae (Lepidoptera: Lycaenidae), butterflies with ant associations and unusual lichenivorous diets
Systematic Entomology·2023· 4 citedOpen Access
CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents
Blood·2022· 4 cited
Biochemical Principles of Targeted Protein Degradation
2022· 1 cited
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
Cancer Research·2022· 11 cited
Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma
Cancer Research·2022· 3 cited
page 1 of 5Next →

Frequent Co-authors

Andrew J. Phillips(7), David E. Ehmann(6), Barbara Imperiali(6), Roman V. Agafonov(6), Keith A. Yagaloff(5), Günther Kern(5), Folkert Reck(5), Christopher G. Nasveschuk(5), Roy M. Pollock(5), Paul Burn(4), Grant K. Walkup(4), Christopher T. Walsh(4), Jennifer Gale(4), Scott J. Eron(4), Ashley Hart(4), David Cocozziello(4), Richard W. Deibler(4), Haris Jahić(3), Philip L. Ross(3), Rong-Fang Gu(3)